Zhang S, Li N, Sheng Y, Chen W, Ma Q, Yu X, et al. Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression. Infect Agents Cancer. 2021;16(1):1–11.
McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73:4–13.
Article CAS PubMed Google Scholar
Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72(2):250–61.
Article CAS PubMed PubMed Central Google Scholar
Wu TW, Lin HH, Wang LY. Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology. 2013;57(1):37–45.
Bai X, Chen L, Liu X, Tong Y, Wang L, Zhou M, et al. Adult hepatitis B virus vaccination coverage in China from 2011 to 2021: a systematic review. Vaccines. 2022;10(6):900.
Article PubMed PubMed Central Google Scholar
Wu J-W, Tseng T-C, Liu C-J, Su T-H, Liu C-H, Chen P-J, et al. Both hepatitis A and hepatitis D infections may be associated with more advanced liver disease in patients with chronic hepatitis B. Adv Digest Med. 2021;8(4):211–7.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–55.
Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–72.
Article CAS PubMed Google Scholar
Yu Z, Feng H, Zhuo Y, Li M, Zhu X, Huang L, et al. Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradation. Cell Oncol. 2020;43(6):1129–45.
Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: a review in hepatocellular carcinoma. Drugs. 2019;79(6):665–74.
Article CAS PubMed Google Scholar
Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5(1):87.
Article PubMed PubMed Central Google Scholar
Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73.
Article CAS PubMed Google Scholar
Bruix J, Raoul J-L, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821–9.
Article CAS PubMed Google Scholar
Cainap C, Qin S, Huang W-T, Chung IJ, Pan H, Cheng Y, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33(2):172.
Article CAS PubMed Google Scholar
Gladu P, Patterson G, Wikfors G, Chitwood D, Lusby W. The occurrence of brassicasterol and epibrassicasterol in the Chromophycota. 1990.
Vanmierlo T, Popp J, Koelsch H, Friedrichs S, Jessen F, Stoffel-Wagner B, et al. The plant sterol brassicasterol as additional CSF biomarker in Alzheimer’s disease. Acta Psychiatr Scand. 2011;124(3):184–92.
Article CAS PubMed Google Scholar
Additives EPoF, Food NSat. Scientific Opinion on the safety of stigmasterol‐rich plant sterols as food additive. EFSA J. 2012;10(5):2659.
Yazawa Y, Ikarashi N, Hoshino M, Kikkawa H, Sakuma F, Sugiyama K. Inhibitory effect of ergosterol on bladder carcinogenesis is due to androgen signaling inhibition by brassicasterol, a metabolite of ergosterol. J Nat Med. 2020;74(4):680–8.
Article CAS PubMed Google Scholar
Xu Y, Ryu S, Lee Y-K, Lee H-J. Brassicasterol from edible aquacultural Hippocampus abdominalis exerts an anti-cancer effect by dual-targeting AKT and AR signaling in prostate cancer. Biomedicines. 2020;8(9):370.
Article CAS PubMed PubMed Central Google Scholar
Hassan ST. Brassicasterol with dual anti-infective properties against HSV-1 and Mycobacterium tuberculosis, and cardiovascular protective effect: nonclinical in vitro and in silico assessments. Biomedicines. 2020;8(5):132.
Article CAS PubMed PubMed Central Google Scholar
Yu P, Lou D, Qi L, Chen Z. The novel antiviral properties of brassicasterol against human adenovirus. Futur Virol. 2021;16(9):591–600.
Hu K, Fu M, Wang J, Luo S, Barreto M, Singh R, et al. HSV-2 infection of human genital epithelial cells upregulates TLR9 expression through the SP1/JNK signaling pathway. Front Immunol. 2020;11.
Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med. 2006;38(3):200–11.
Article CAS PubMed Google Scholar
Song M, Bode AM, Dong Z, Lee M-H. AKT as a therapeutic target for cancerchallenging cancer therapy by targeting AKT. Can Res. 2019;79(6):1019–31.
Testoni B, Levrero M, Zoulim F, editors. Challenges to a cure for HBV infection. Seminars in Liver Disease; 2017: Thieme Medical Publishers.
Ou D-P, Yang L-Y, Huang G-W, Tao Y-M, Ding X, Chang Z-G. Clinical analysis of the risk factors for recurrence of HCC and its relationship with HBV. World J Gastroenterol: WJG. 2005;11(14):2061.
Article PubMed PubMed Central Google Scholar
Llovet J, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.
Jun CH, Hong HJ, Chung MW, Park SY, Cho SB, Park CH, et al. Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B. World J Gastroenterol: WJG. 2013;19(40):6834.
Article PubMed PubMed Central Google Scholar
Lian J, Zou Y, Huang L, Cheng H, Huang K, Zeng J, et al. Hepatitis B virus upregulates cellular inhibitor of apoptosis protein 2 expression via the PI3K/AKT/NF-κB signaling pathway in liver cancer. Oncol Lett. 2020;19(3):2043–52.
CAS PubMed PubMed Central Google Scholar
Revathidevi S, Munirajan AK. Akt in cancer: mediator and more. Semin Cancer Biol. 2019;59:80–91.
Article CAS PubMed Google Scholar
Hoxhaj G, Manning BD. The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20(2):74–88.
Article CAS PubMed Google Scholar
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.
Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology. 2005;41(2):307–14.
Article CAS PubMed Google Scholar
Macek Jilkova Z, Kurma K, Decaens T. Animal models of hepatocellular carcinoma: the role of immune system and tumor microenvironment. Cancers (Basel). 2019;11(10).
留言 (0)